Veracyte Stock Buy Hold or Sell Recommendation
VCYT Stock | USD 19.83 0.02 0.10% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Veracyte is 'Hold'. Macroaxis provides Veracyte buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Veracyte positions. The advice algorithm takes into account all of Veracyte's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Veracyte's buy or sell advice are summarized below:
Real Value 23.43 | Target Price 32.67 | Hype Value 19.71 | Market Value 19.83 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Veracyte given historical horizon and risk tolerance towards Veracyte. When Macroaxis issues a 'buy' or 'sell' recommendation for Veracyte, the advice is generated through an automated system that utilizes algorithms and statistical models.
Veracyte |
Execute Veracyte Buy or Sell Advice
The Veracyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Veracyte. Macroaxis does not own or have any residual interests in Veracyte or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Veracyte's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Veracyte Trading Alerts and Improvement Suggestions
Veracyte generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 361.05 M. Net Loss for the year was (74.4 M) with profit before overhead, payroll, taxes, and interest of 194.95 M. | |
Over 97.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from businesswire.com: Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 |
Veracyte Returns Distribution Density
The distribution of Veracyte's historical returns is an attempt to chart the uncertainty of Veracyte's future price movements. The chart of the probability distribution of Veracyte daily returns describes the distribution of returns around its average expected value. We use Veracyte price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Veracyte returns is essential to provide solid investment advice for Veracyte.
Mean Return | -0.34 | Value At Risk | -4.98 | Potential Upside | 3.72 | Standard Deviation | 2.90 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Veracyte historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Veracyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Veracyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Veracyte backward and forwards among themselves. Veracyte's institutional investor refers to the entity that pools money to purchase Veracyte's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Champlain Investment Partners, Llc | 2023-12-31 | 2.2 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | Gw&k Investment Management, Llc | 2023-12-31 | 1.4 M | Nuveen Asset Management, Llc | 2023-12-31 | 1 M | Northern Trust Corp | 2023-12-31 | 979.8 K | Fisher Asset Management, Llc | 2023-12-31 | 875.2 K | Granite Investment Partners, Llc | 2023-12-31 | 873.3 K | Bank Of America Corp | 2023-12-31 | 839.5 K | New York State Common Retirement Fund | 2023-12-31 | 837.5 K | Ark Investment Management Llc | 2023-12-31 | 7.7 M | Blackrock Inc | 2023-12-31 | 7.2 M |
Veracyte Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (3.4M) | 1.1M | (1.5M) | (3.0M) | (1.7M) | (1.6M) | |
Change In Cash | 81.3M | 190.0M | (176.0M) | (19.0M) | 62.2M | 65.3M | |
Free Cash Flow | (6.0M) | (12.5M) | (37.0M) | (1.0M) | 34.3M | 36.0M | |
Depreciation | 4.1M | 7.9M | 19.6M | 25.9M | 27.2M | 28.5M | |
Other Non Cash Items | 312K | 2.7M | 3.9M | 7.7M | 66.3M | 69.6M | |
Capital Expenditures | 2.8M | 2.8M | 5.4M | 8.5M | 10.0M | 10.5M | |
Net Income | (12.6M) | (34.9M) | (75.6M) | (36.6M) | (74.4M) | (70.7M) | |
End Period Cash Flow | 159.9M | 350.0M | 173.9M | 155.0M | 216.5M | 117.9M | |
Change Receivables | (6.2M) | 955K | (8.6M) | (4.5M) | (4.0M) | (4.2M) | |
Net Borrowings | (292K) | (25.2M) | (100K) | (1.3M) | (1.2M) | (1.1M) | |
Change To Netincome | 9.8M | 15.6M | 26.4M | 27.6M | 31.8M | 33.3M | |
Investments | (42.7M) | (1M) | 3M | (20.8M) | (8.8M) | (9.3M) |
Veracyte Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Veracyte or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Veracyte's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Veracyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.53 | |
β | Beta against NYSE Composite | 2.28 | |
σ | Overall volatility | 2.94 | |
Ir | Information ratio | -0.15 |
Veracyte Volatility Alert
Veracyte exhibits very low volatility with skewness of -0.53 and kurtosis of 1.42. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Veracyte's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Veracyte's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Veracyte Fundamentals Vs Peers
Comparing Veracyte's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Veracyte's direct or indirect competition across all of the common fundamentals between Veracyte and the related equities. This way, we can detect undervalued stocks with similar characteristics as Veracyte or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Veracyte's fundamental indicators could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Veracyte to competition |
Fundamentals | Veracyte | Peer Average |
Return On Equity | -0.0702 | -0.31 |
Return On Asset | -0.0099 | -0.14 |
Profit Margin | (0.21) % | (1.27) % |
Operating Margin | 0 % | (5.51) % |
Current Valuation | 1.26 B | 16.62 B |
Shares Outstanding | 75.07 M | 571.82 M |
Shares Owned By Insiders | 1.14 % | 10.09 % |
Shares Owned By Institutions | 97.13 % | 39.21 % |
Number Of Shares Shorted | 3.64 M | 4.71 M |
Price To Earning | (10.61) X | 28.72 X |
Price To Book | 1.45 X | 9.51 X |
Price To Sales | 4.21 X | 11.42 X |
Revenue | 361.05 M | 9.43 B |
Gross Profit | 194.95 M | 27.38 B |
EBITDA | 15.12 M | 3.9 B |
Net Income | (74.4 M) | 570.98 M |
Cash And Equivalents | 170.11 M | 2.7 B |
Cash Per Share | 2.37 X | 5.01 X |
Total Debt | 12.63 M | 5.32 B |
Debt To Equity | 0.02 % | 48.70 % |
Current Ratio | 4.09 X | 2.16 X |
Book Value Per Share | 14.25 X | 1.93 K |
Cash Flow From Operations | 44.22 M | 971.22 M |
Short Ratio | 4.98 X | 4.00 X |
Earnings Per Share | (1.02) X | 3.12 X |
Target Price | 30.83 | |
Number Of Employees | 815 | 18.84 K |
Beta | 1.64 | -0.15 |
Market Capitalization | 1.49 B | 19.03 B |
Total Asset | 1.14 B | 29.47 B |
Retained Earnings | (468.12 M) | 9.33 B |
Working Capital | 224.38 M | 1.48 B |
Current Asset | 47.91 M | 9.34 B |
Note: Disposition of 10000 shares by Evan Jones of Veracyte at 24.3599 subject to Rule 16b-3 [view details]
Veracyte Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Veracyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution | 24240.59 | |||
Daily Balance Of Power | (0.02) | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 20.26 | |||
Day Typical Price | 20.11 | |||
Price Action Indicator | (0.44) | |||
Period Momentum Indicator | (0.02) |
About Veracyte Buy or Sell Advice
When is the right time to buy or sell Veracyte? Buying financial instruments such as Veracyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 42.4M | 44.0M | 41.2M | 43.2M | Total Assets | 1.2B | 1.2B | 1.1B | 1.2B |
Use Investing Ideas to Build Portfolios
In addition to having Veracyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All Next | Launch |
Check out Veracyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Veracyte Stock analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 4.97 | Quarterly Revenue Growth 0.223 | Return On Assets (0.01) | Return On Equity (0.07) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.